Myriad Genetics Inc reports results for the quarter ended June 30 - Earnings Summary

• Myriad Genetics Inc MYGN.OQ reported quarterly adjusted earnings of 5 cents​​ per share for the quarter ended June 30, identical to the same quarter last year. The mean expectation of sixteen analysts for the quarter was for a loss of one cent per share. Wall Street expected results to range from -3 cents to 5 cents per share.

• Revenue rose 0.8% to $213.10 million from a year ago; analysts expected $201.88 million.

• Myriad Genetics Inc's reported EPS for the quarter was a loss of $3.57​.

• The company reported a quarterly loss of $330.5 million.

• Myriad Genetics Inc shares had fallen by 25.0% this quarter and lost 71.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 182.6% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 9 "hold" and 4 "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

• Wall Street's median 12-month price target for Myriad Genetics Inc is $6.00, about 33.7% above its last closing price of $3.98

This summary was machine generated from LSEG data August 5 at 09:43 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)